Abstract:Nanoreactors offer a great platform for the onsite generation of functional products. However, the production of the desired compound is often limited by either the availability of the reagents or...
“…Controlled release of plasmidDNA 66 Absence of chemical modification of the drug Limited encapsulation efficiencies Targeted delivery of siRNA 67 Variety of morphologies and architectures High risk of dissociation in blood mRNA delivery (animal study) 68 High protection Polymersome delivery of the SARS-CoV-2 spike protein (preclinical trials) 69 Nanoparticle/ nanogel/ nanocapsule Physical encapsulation Protein encapsulation 70 Absence of chemical modification of the drug Risk of denaturation due to crosslinking reactions involved Enzyme nanocapsules 71 High protection Delivery and controlled release of deoxyribonuclease I 72 High stability Vaccine development based on nanogel protein delivery (animal study) 73 Easy incorporation of smart units Iduronate 2-sulfatase delivery with PLGA nanoparticles (preclinical testing) 74 Controlled release harness the immune stimulatory benefits of the protein to increase the anti-tumor responses while minimizing undesired therapeutical side effects. 84 In this PEG-functionalized form, the IL2 is inactive and a biological prodrug.…”
Section: Physical Encapsulationmentioning
confidence: 99%
“…For instance, such an approach allowed for the encapsulation of multiple enzymes in one nanocapsule with the aim of performing enzymatic cascade reactions. 71 Similar strategies have been used to prepare both polymer and silica nanocapsules. 71,161 All of the enzymes involved maintained their enzymatic activity after the encapsulation while they were successfully protected against proteases and heat.…”
Section: Nanoparticles Nanogels and Nanocapsulesmentioning
confidence: 99%
“…71 Similar strategies have been used to prepare both polymer and silica nanocapsules. 71,161 All of the enzymes involved maintained their enzymatic activity after the encapsulation while they were successfully protected against proteases and heat. This strategy, of encapsulating biomacromolecular payload dissolved in the aqueous phase of an inverse miniemulsion by the formation of a shell at the droplet interface, has been used successfully to encapsulate enzyme and SiRNA in polymer and silica nanocapsules.…”
Section: Nanoparticles Nanogels and Nanocapsulesmentioning
confidence: 99%
“…Upon the initiation of the polymerization or crosslinking reaction, the polymer network becomes insoluble and precipitates as solid particles. 71,157,163,164 Examples of application. The distinct structures produced by the different methods display different properties.…”
Section: Nanoparticles Nanogels and Nanocapsulesmentioning
confidence: 99%
“…In another approach, nanocapsules were prepared from the biomacromolecular therapeutic agent itself. 71 For instance, proteins and enzymes were crosslinked in an inverse miniemulsion to obtain solid protein nanocapsules with a retained biological activity of the biomacromolecules (Fig. 6c and d).…”
Section: Nanoparticles Nanogels and Nanocapsulesmentioning
The ability of biomacromolecular therapeutic agents to treat various diseases is limited by the challenges faced in their delivery. Here we review how the design of polymer-based nanosystems can provide modular solutions to face those delivery issues.
“…Controlled release of plasmidDNA 66 Absence of chemical modification of the drug Limited encapsulation efficiencies Targeted delivery of siRNA 67 Variety of morphologies and architectures High risk of dissociation in blood mRNA delivery (animal study) 68 High protection Polymersome delivery of the SARS-CoV-2 spike protein (preclinical trials) 69 Nanoparticle/ nanogel/ nanocapsule Physical encapsulation Protein encapsulation 70 Absence of chemical modification of the drug Risk of denaturation due to crosslinking reactions involved Enzyme nanocapsules 71 High protection Delivery and controlled release of deoxyribonuclease I 72 High stability Vaccine development based on nanogel protein delivery (animal study) 73 Easy incorporation of smart units Iduronate 2-sulfatase delivery with PLGA nanoparticles (preclinical testing) 74 Controlled release harness the immune stimulatory benefits of the protein to increase the anti-tumor responses while minimizing undesired therapeutical side effects. 84 In this PEG-functionalized form, the IL2 is inactive and a biological prodrug.…”
Section: Physical Encapsulationmentioning
confidence: 99%
“…For instance, such an approach allowed for the encapsulation of multiple enzymes in one nanocapsule with the aim of performing enzymatic cascade reactions. 71 Similar strategies have been used to prepare both polymer and silica nanocapsules. 71,161 All of the enzymes involved maintained their enzymatic activity after the encapsulation while they were successfully protected against proteases and heat.…”
Section: Nanoparticles Nanogels and Nanocapsulesmentioning
confidence: 99%
“…71 Similar strategies have been used to prepare both polymer and silica nanocapsules. 71,161 All of the enzymes involved maintained their enzymatic activity after the encapsulation while they were successfully protected against proteases and heat. This strategy, of encapsulating biomacromolecular payload dissolved in the aqueous phase of an inverse miniemulsion by the formation of a shell at the droplet interface, has been used successfully to encapsulate enzyme and SiRNA in polymer and silica nanocapsules.…”
Section: Nanoparticles Nanogels and Nanocapsulesmentioning
confidence: 99%
“…Upon the initiation of the polymerization or crosslinking reaction, the polymer network becomes insoluble and precipitates as solid particles. 71,157,163,164 Examples of application. The distinct structures produced by the different methods display different properties.…”
Section: Nanoparticles Nanogels and Nanocapsulesmentioning
confidence: 99%
“…In another approach, nanocapsules were prepared from the biomacromolecular therapeutic agent itself. 71 For instance, proteins and enzymes were crosslinked in an inverse miniemulsion to obtain solid protein nanocapsules with a retained biological activity of the biomacromolecules (Fig. 6c and d).…”
Section: Nanoparticles Nanogels and Nanocapsulesmentioning
The ability of biomacromolecular therapeutic agents to treat various diseases is limited by the challenges faced in their delivery. Here we review how the design of polymer-based nanosystems can provide modular solutions to face those delivery issues.
Proteine und Enzyme sind äußerst vielseitige Biomaterialien, die aufgrund ihrer hohen Spezifität für Rezeptoren und Substrate, ihrer Abbaubarkeit, geringen Toxizität und insgesamt guten Biokompatibilität hervorragend für ein breites Spektrum medizinischer Anwendungen geeignet sind. Durch die Anordnung mehrerer nativer oder modifizierter Proteine zu nanometergroßen Protein‐Nanopartikeln können zusätzliche vorteilhafte Eigenschaften wie eine erhöhte Stabilität im Blutstrom erreicht werden. In diesem Aufsatz konzentrieren wir uns auf künstliche Nanopartikelsysteme, bei denen Proteine das Hauptstrukturelement sind und nicht nur als eingeschlossene Wirkstoffe transportiert werden. Während unter natürlichen Bedingungen lediglich bestimmte Proteine definierte Aggregate und Nanopartikel bilden, können durch chemische Modifikationen oder Veränderungen in der physikalischen Umgebung Nanopartikel aus vielen verschiedenen globulären Proteinen und Enzymen hergestellt werden. Fortschritte bei den Herstellungsmethoden von proteinbasierten Nanopartikeln haben zu einer neuen Generation von Nanosystemen geführt, die über einfache Wirkstofftransporter hinausgehen und vielfältige Anwendungen ermöglichen, wie z.B. gezielte Arzneimittelabgabe, Theranostik, Nanokatalyse und Proteintherapie.
Herein, we report a novel enzymatic dimerization‐induced self‐assembly (e‐DISA) procedure that converts alanine‐tyramine conjugates into highly uniform enzyme‐loaded nanoparticles (NPs) or nanocontainers by the action of horseradish peroxidase (HRP) in an aqueous medium under ambient conditions. The NP formation was possible with both enantiomers of alanine, and the average diameter could be varied from 150 nm to 250 nm (with a 5–12 % standard deviation of as‐prepared samples) depending on the precursor concentration. About 60 % of the added HRP enzyme was entrapped within the NPs and was subsequently utilized for post‐synthetic modification of the NPs with phenolic compounds such as tyramine or tannic acid. One‐pot multi‐enzyme entrapment of glucose oxidase (GOx) and peroxidase (HRP) within the NPs was also achieved. These GOx‐HRP loaded NPs allowed multimodal detection of glucose, including that present in human saliva, with a limit of detection (LoD) of 740 nM through fluorimetry. The NPs exhibited good cytocompatibility and were stable to changes in pH (acidic to basic), temperature, ultrasonication, and even the presence of organic solvent (EtOH) to a certain extent, since they are stabilized by intermolecular hydrogen bonding, π‐π, and CH‐π interactions. The proposed e‐DISA procedure can be widely expanded through the design of diverse enzyme‐responsive precursors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.